The company's stock has risen over 32% in three months, but faces headwinds from declining financial estimates, upcoming patent expiration for its key drug Keytruda, and sales declines for Gardasil. Keytruda drives over half of pharmaceutical revenue, but softer Q3 sales raise questions about Q4 performance. The CEO projects over $5 billion in revenue from a recent acquisition. Analysts maintain a sell rating due to concerns over the drug pipeline and competitive biosimilar threats post-patent expiry.